Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Cirrhosis - PubMed (original) (raw)
Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Cirrhosis
Manuel Rodríguez et al. Am J Gastroenterol. 2021.
Abstract
Introduction: Although alcohol cessation is the only effective treatment for alcohol-related liver disease, few data exist concerning its influence on the risk of hepatocellular carcinoma (HCC). We aimed to evaluate the effect of alcohol abstinence on the incidence of HCC in patients with alcohol-related cirrhosis.
Methods: We studied 727 patients with alcohol-related cirrhosis (247 with compensated disease and 480 with previous decompensation) who were included in a surveillance program for the early detection of HCC and prospectively followed. Baseline clinical and biological parameters and alcohol consumption during follow-up were recorded. Abstinence was defined as the absence of any alcohol use.
Results: During follow-up (median 54 months), 354 patients (48.7%) remained abstinent and 104 developed HCC (2.3 per 100 person-years). Factors independently associated with the risk of HCC among patients with previous decompensation were age, male gender, and aspartate aminotransferase, whereas abstinence was not linked to a reduced risk (hazard ratio 0.95; 95% confidence interval 0.59-1.52). However, among patients without previous decompensation, prothrombin activity and abstinence were independently associated with the risk of HCC. Abstinent patients had a significant decrease in the risk of developing tumor (hazard ratio 0.35; 95% confidence interval 0.13-0.94). These results did not change after applying a competing risk analysis where death and liver transplantation were considered as competing events.
Discussion: Alcohol abstinence reduced the risk of HCC in patients with alcohol-related cirrhosis, but only in those without a history of decompensated disease. This finding emphasizes the need for an early diagnosis of alcohol-related liver disease and for implementing strategies leading to an increase in the rate of achieving and maintaining abstinence among this population.
Copyright © 2021 by The American College of Gastroenterology.
Similar articles
- Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
Ganne-Carrié N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau JM, Oberti F, Roulot D, Moreno C, Louvet A, Dao T, Moirand R, Goria O, Nguyen-Khac E, Carbonell N, Antonini T, Pol S, de Ledinghen V, Ozenne V, Henrion J, Péron JM, Tran A, Perlemuter G, Amiot X, Zarski JP, Beaugrand M, Chevret S; for CIRRAL Group. Ganne-Carrié N, et al. J Hepatol. 2018 Dec;69(6):1274-1283. doi: 10.1016/j.jhep.2018.07.022. Epub 2018 Aug 6. J Hepatol. 2018. PMID: 30092234 - Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN, Green P, Kerr KF, Berry K. Ioannou GN, et al. J Hepatol. 2019 Sep;71(3):523-533. doi: 10.1016/j.jhep.2019.05.008. Epub 2019 May 28. J Hepatol. 2019. PMID: 31145929 Free PMC article. - Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients.
Alvarez MA, Cirera I, Solà R, Bargalló A, Morillas RM, Planas R. Alvarez MA, et al. J Clin Gastroenterol. 2011 Nov-Dec;45(10):906-11. doi: 10.1097/MCG.0b013e3182284e13. J Clin Gastroenterol. 2011. PMID: 21814145 - Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
Fattovich G, Stroffolini T, Zagni I, Donato F. Fattovich G, et al. Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50. doi: 10.1053/j.gastro.2004.09.014. Gastroenterology. 2004. PMID: 15508101 Review. - Alcohol and hepatocellular carcinoma.
Morgan TR, Mandayam S, Jamal MM. Morgan TR, et al. Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96. doi: 10.1053/j.gastro.2004.09.020. Gastroenterology. 2004. PMID: 15508108 Review.
Cited by
- Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.
Shiina S, Tateishi R, Choi JI, Kim SY, Meng Z, Shen L, Lu SN, Hwang JI, Tobari M, Maruyama H, Batsaikhan T, Deng Q, Canseco LM, Asaoka Y, Lin SM, Huang KW, Rhim H, Liang P, Pua U, Tanaka M, Wu P. Shiina S, et al. Liver Cancer. 2025 Mar 3:1-27. doi: 10.1159/000544976. Online ahead of print. Liver Cancer. 2025. PMID: 40242794 Free PMC article. - Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions.
Liu YB, Chen MK. Liu YB, et al. World J Gastroenterol. 2022 Nov 7;28(41):5910-5930. doi: 10.3748/wjg.v28.i41.5910. World J Gastroenterol. 2022. PMID: 36405106 Free PMC article. Review. - Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
Zhang C, Zhang W, Shui Y, Li P, Tian Z, Duan S, Wei Q. Zhang C, et al. Front Immunol. 2022 Nov 2;13:1001506. doi: 10.3389/fimmu.2022.1001506. eCollection 2022. Front Immunol. 2022. PMID: 36405741 Free PMC article. - The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study.
Yang K, Kim S, Yang H, Wang SM, Jeong B, Lim HK, Bae SH. Yang K, et al. Clin Mol Hepatol. 2024 Oct;30(4):929-942. doi: 10.3350/cmh.2024.0278. Epub 2024 Aug 27. Clin Mol Hepatol. 2024. PMID: 39188230 Free PMC article. - Thomasclavelia ramosa and alcohol-related hepatocellular carcinoma: a microbial culturomics study.
Magdy Wasfy R, Abdoulaye A, Borentain P, Mbaye B, Tidjani Alou M, Caputo A, Andrieu C, Mottola G, Levasseur A, Million M, Gerolami R. Magdy Wasfy R, et al. Gut Pathog. 2025 May 7;17(1):27. doi: 10.1186/s13099-025-00703-6. Gut Pathog. 2025. PMID: 40336003 Free PMC article.
References
- GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:245–66.
- Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 2018;69:718–35.
- Moon AM, Yang JY, Barritt AS IV, et al. Rising mortality from alcohol-associated liver disease in the United States in the 21st century. Am J Gastroenterol 2020;115:79–87.
- LoConte NK, Brewster AM, Kaur JS, et al. Alcohol and cancer: A statement of the American Society of Clinical Oncology. J Clin Oncol 2018;36:83–93.
- Paik JM, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of nonalcoholic fatty liver disease. Hepatology 2020;72:1605–16.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical